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Abstract The nucleotide adenosine 5′-triphosphate (ATP) has classically been considered the cell’s primary energy currency.
Importantly, a novel role for ATP as an extracellular autocrine and/or paracrine signalling molecule has evolved over
the past century and extensive work has been conducted to characterize the ATP-sensitive purinergic receptors
expressed on almost all cell types in the body. Extracellular ATP elicits potent effects on vascular cells to regulate
blood vessel tone but can also be involved in vascular pathologies such as atherosclerosis. While the effects of pur-
inergic signalling in the vasculature have been well documented, the mechanism(s) mediating the regulated release of
ATP from cells in the blood vessel wall and circulation are now a key target of investigation. The aim of this review is
to examine the current proposed mechanisms of ATP release from vascular cells, with a special emphasis on the
transporters and channels involved in ATP release from vascular smooth muscle cells, endothelial cells, circulating
red blood cells, and perivascular sympathetic nerves, including vesicular exocytosis, plasma membrane F1/F0-ATP syn-
thase, ATP-binding cassette (ABC) transporters, connexin hemichannels, and pannexin channels.
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1. Introduction
Classically, the nucleotide adenosine 5′-triphosphate (ATP) has been
considered the major energy source in the cell. Through the metabol-
ic breakdown of ingested nutrients, subsequent production of the
electron carriers NADH and FADH2 in the citric acid cycle and the
transfer of electrons through the electron transport chain, the mito-
chondrial ATP synthase synthesize ATP in the mitochondrial matrix,
which is then transported to and accumulates in the cytosol at a con-
centration in the low mM range.1,2 The cell utilizes the high-energy
content of this molecule for a multitude of functions including its re-
quirement as a cofactor for active transport of molecules across the
plasma membrane, actin–myosin cross bridge cycling during muscle
contraction, and hydrolysis and transfer of its terminal phosphate
group to proteins driven by protein kinases as a post-translational
modification to modulate protein function. Through extensive charac-
terization of the role of this nucleotide as an intracellular energy mol-
ecule, a novel role for ATP as a potent extracellular signalling
molecule emerged nearly 50 years ago. Over the past five decades,
extensive work has shown that ATP can be released from a
number of different cell types and can exert effects via autocrine
and/or paracrine signalling mechanisms. In 1971, Burnstock3 coined
the term ‘purinergic’, referring to nerves in the autonomic nervous
system that released neither noradrenaline nor acetylcholine upon
stimulation, but instead the purine nucleotide ATP. This classification
has since been expanded to encompass all aspects of purine signalling.
While the effects of ATP as an extracellular signalling molecule have
been extensively characterized, the mechanisms involved in its regu-
lated release from different cell types remain an important topic of
investigation.4 –6
1.1 ATP signalling in the vasculature
The effects of ATP signalling have been observed throughout the
vasculature in both homeostatic and pathological conditions, including
reactive hyperaemia,7,8 hypoxia-induced vasodilation,9,10 alpha-
adrenergic receptor mediated vasoconstriction,11 hypertension,12
VSMC proliferation in atherosclerosis, and arterial restenosis after
balloon angioplasty.13,14 Elucidation of the mechanisms regulating
purine nucleotide release in the cells comprising the vascular wall is
critical for both understanding the pathogenesis of vascular diseases
and the identification of novel drug interventions. In 1977, Forrester
and Williams15 observed the release of ATP from cells in the cardio-
vascular system and the release of ATP has since been shown in all major
cell types of the vessel wall including endothelial cells,9,16– 19 vascular
smooth muscle cells,11,20 perivascular sympathetic nerves,21–24 and
circulating erythrocytes.10,25–27 Therefore, a keen understanding of
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the signalling mechanisms involved in the release of ATP is critical. In this
review, we will focus on the possible mechanisms involved with the ATP
release from endothelial and smooth muscle cells in the blood vessel
wall, as well as circulating erythrocytes and perivascular sympathetic
nerves that innervate the vasculature.
The foundation for an active role of purinergic signalling in the vas-
culature was first observed by Drury and Szent-Gyorgyi28 in 1929,
who demonstrated that the adenine nucleotides and nucleosides,
when injected intravenously into the circulatory system of dogs, pro-
duced a potent sinus bradycardia and a fall in blood pressure. This ob-
servation pioneered the concept that ATP may be an important
signalling molecule in the cardiovascular system and could produce
profound effects on cardiac output and blood pressure. Later, the
identification and characterization of ATP-sensitive purinergic recep-
tors at the plasma membrane of vascular smooth muscle and endo-
thelial cells across vascular beds further suggested a role for ATP as
an extracellular vasoactive signalling molecule which may contribute
to blood pressure regulation at the level of the blood vessels them-
selves.29– 32 Purinergic receptors have since been classified into two
main families, designated as P1 and P2 receptors (with P annotating
Purinergic). P1 receptors are further subclassified as A1, A2A, A2B,
or A3 receptors, and are G-protein-coupled receptors that signal
through either Gs or Gi and selectively bind the nucleoside adenosine
to modulate levels of cAMP within the cell.33 The P2 receptors have
been subclassified as either ionotropic P2X receptors, of which seven
isoforms have been characterized to date (P2X1 –7),
34 or metabotro-
pic P2Y receptors, which contain eight isoforms (P2Y1, 2, 4, 6, 11– 14)
35
(reviewed by Ralevic and Burnstock36). The P2X receptors are ligand
gated ion channels which exhibit a high binding affinity for ATP over
its metabolic breakdown products. P2X receptor activation by ATP
induces a conformational change in the transmembrane channel that
allows the influx of extracellular cations, including Na+ and Ca2+
leading to cellular depolarization. This depolarization in turn can acti-
vate voltage-gated calcium channels to facilitate further Ca2+ influx
strengthening the depolarization.37,38 The P2Y family of receptors
are G-protein-coupled receptors that differentially bind to ATP,
ADP, or the uracil nucleotides UTP and UDP, depending on receptor
subtype, and signal through Gq, Gi, or Gs ultimately producing changes
in the concentration of intracellular cAMP or Ca2+. While numerous
purinergic receptor isoforms have been identified in vascular cells, it
has been shown that binding of ATP to P2X1 receptors localized
on VSMCs causes an influx of Ca2+ that results in constriction of
the blood vessel.39,40 Conversely, ATP in the blood vessel lumen
can bind to P2Y1 and P2Y2 purinergic receptors localized to endothe-
lial cells, which signals the production of inositol triphosphate (IP3)
and release of Ca2+ from the endoplasmic reticulum via activation
of IP3 receptors. This rise in intracellular calcium concentration
leads to activation of endothelial cell nitric oxide synthase, resulting
in the production of nitric oxide which feeds back on VSMCs to
induce vasodilation.41– 43 Contrary to this traditional classification of
differential P2 receptor effects in the vascular wall, luminal perfusion
of ATP has also been shown to elicit vasodilation via activation of
endothelial cell P2X receptors,44 and ATP activation of smooth
muscle cell P2Y purinergic receptors has been shown to promote
vasoconstriction in different vascular beds.11 Altogether, these obser-
vations may suggest that purinergic signalling in the vasculature occurs
at distinct micro-signalling domains where localized ATP release sti-
mulates purinergic receptors based on their relative location to the
site of release or that purinergic receptor expression in the vessel
wall may vary depending on the vascular bed examined. Future
studies are required to elucidate this observed difference. This dual
control of vascular tone by the purine nucleotide ATP has been
reviewed extensively by Burnstock.45
Extracellular purine nucleotide concentration is tightly regulated in
the vasculature. The presence and activity of metabolic enzymes that
degrade ATP to ADP, AMP and adenosine, as well as expression of
multiple P1 and P2 receptors across vascular beds has sparked the
question as to which nucleotide or nucleoside is the primary vaso-
active molecule. Berne46 first proposed an active role for adenosine
in regulating vascular tone by showing that the nucleoside can
induce coronary vasodilation in the isolated perfused heart. More-
over, measurement of ATP levels in the venous effluent from the iso-
lated rat hindlimb in response to hyperaemia induced by muscle
contraction were undetectable, while adenosine levels were signifi-
cantly increased.47 In a separate study, however, Hopwood and
Burnstock29 observed that a significant portion of the dilation elicited
by luminal ATP in the isolated perfused Langendorff heart preparation
was resistant to P1 receptor blockade with the non-selective adeno-
sine receptor antagonist PACPX, supporting the role that ATP acting
on P2 receptors on endothelial cells elicits the observed vasodilatory
response. Furthermore, the vasodilation observed in response to
luminal ATP has been shown to be approximately 100 times more
potent than that to adenosine.48 Several years later, Bunger et al.49
were able to carefully repeat these observations, but found the mag-
nitude of difference significantly decreased compared with what was
previously reported. Altogether, these observations illustrate the
dynamic regulation of purine nucleotide metabolism and support
the idea that ATP can elicit potent effects on vascular cells before
its metabolic breakdown.
In the blood vessel lumen, ATP concentration has been shown to
increase during periods of hypoxia and ischaemia. The source of
this luminal ATP has been suggested to arise from liberation from cir-
culating erythrocytes10,50 as well as the endothelial cells that line the
vessel lumen.9,16,17 Locovei et al.50 reported ATP release from ery-
throcytes in response to low oxygen tension and osmotic stress, pro-
viding a luminal source of ATP, presumably to act on endothelial cell
purinergic receptors to induce vasodilation, an increase in blood flow
and O2 delivery to tissues. Increased shear stress on endothelial cells
has also been shown to induce ATP release into the vessel
lumen.9,16,19 At the smooth muscle cell-perivascular sympathetic
nerve axis, ATP has been shown to be released as a co-transmitter
along with noradrenaline from sympathetic nerves.21– 23,51 Release
of ATP from perivascular nerve terminals and increases in concentra-
tion of the nucleotide at adjacent vascular smooth muscle cells
induces vasoconstriction through activation of P2X1 purinergic recep-
tors.23,29 Sneddon and Burnstock23 reported a portion of the excita-
tory junction potentials and constrictions elicited by perivascular
nerve stimulation that is insensitive to a-adrenergic receptor blockade
and is mimicked by application of exogenous ATP, suggesting an es-
sential role for this nucleotide in sympathetic nerve-induced contrac-
tion of blood vessels.
It has been suggested that chronic increases in ATP in the vascula-
ture could potentiate pathological conditions such as hypertension
and atherosclerosis; therefore, it is essential that the extracellular con-
centration of this nucleotide is tightly regulated. ATP is actively meta-
bolized by a class of catalytic enzymes known as ectonucleotidases.
These membrane-bound proteins present their catalytic core to the
extracellular side of the plasma membrane, allowing selective
A.W. Lohman et al.270
degradation of extracellular nucleotides. Cells can also release soluble
nucleotidases or exonucleotidases into the extracellular milieu, which
can contribute to ATP metabolism outside of the cell.52 The expres-
sion and activity of ectonucleotidases has been extensively character-
ized in the vasculature.53– 56 Of the ectoenzymes present in the
vasculature, ectonucleotide triphosphate diphosphohydrolase 1
(E-NTPDase, also termed CD39 or ecto-apyrase) plays a substantial
role in the breakdown of ATP and ADP to produce AMP.54 The
monophosphorylated nucleotide can then be metabolized further to
adenosine by removal of its 5′-phosphate by the enzyme
ecto-5′-nucleotidase (CD73).57 CD39 localized to arterial smooth
muscle cells reduces the concentration of ATP, ADP, UTP, and
UDP available for activation of P2 receptors and can reduce the
extent and duration of constriction. It has been shown that injection
of the purine nucleotide UDP into the circulation of mice lacking
CD39 caused an initial vasodilation followed by a strong constriction
and a significant increase in mean arterial pressure. Also, endothelium-
denuded aortic rings from these mice showed a significant increase in
constriction to adenine and uridine nucleotides when compared
with controls that express a functional enzyme.12 In a separate
study, Kauffenstein et al.58 observed a marked decrease in blood pres-
sure upon intravenous injection of UTP at a sub-threshold concentra-
tion for vasoconstriction, consistent with decreased nucleotide
breakdown and increased signalling through P2Y receptors on the
endothelium. These studies indicate an essential role for ectonucleo-
tidases in regulating the concentration of ATP both in the blood vessel
lumen and in the extracellular space surrounding the vascular media
and reinforce the dual effect of purines on peripheral resistance and
blood pressure.
While it is now widely accepted that ATP in the vascular system
plays important roles, the mechanisms of its release into the extracel-
lular milieu are a topic of current investigation with much effort placed
on identification of the channels or transporters responsible for its
release from the different vascular cell types. The focus of this
review is to examine the evidence for ATP release from vascular
cells with an emphasis placed on vesicular exocytosis, ATP-binding
cassette (ABC) transporters, the plasma membrane F1/F0-ATP syn-
thase, connexin hemichannels, and the recently identified pannexin
channels.
2. Mechanisms of ATP release
2.1 Vesicular exocytosis
Proteins synthesized in the endoplasmic reticulum and processed
through the Golgi apparatus can be packaged into intracellular vesicles
that traffic and fuse with the plasma membrane in a process termed
vesicular exocytosis. This event can result in incorporation of mem-
brane bound proteins into the plasma membrane or release of
soluble proteins and intracellular molecules into the extracellular
space. Vesicular exocytosis occurs on a second-to-second basis in se-
cretory cell types to release soluble proteins, signalling molecules, and
neurotransmitters important in maintaining homeostasis. In the vascu-
lar system, perivascular sympathetic nerve stimulation leads to the
vesicular release of noradrenaline (NA) and produces an excitatory
junction potential at the post-junctional membrane of innervated
vascular smooth muscle cells and subsequent vasoconstriction.
This response has been well characterized by the activation of
a-adrenergic receptors localized at the post-junctional membrane
of innervated smooth muscle cells and can be mimicked by application
of exogenous NA. However, a-adrenergic receptor blockade at the
post-junctional membrane has been shown to completely inhibit the
response to exogenously applied NA but not that seen by sympathet-
ic nerve stimulation, suggesting the action of a second signalling mol-
ecule, notably ATP.23 The observation by Westfall et al.59 that
tritiated [H3] purine nucleotides are taken up by sympathetic
nerves, along with NA, and released upon field stimulation of the
guinea pig vas deferens suggests a key role for vesicular release of
ATP from these nerves. The contraction following sympathetic
nerve stimulation in the guinea pig vas deferens as well as the rat
tail artery is biphasic, characterized by a fast initial contraction fol-
lowed by a slower sustained contraction. Application of the P2 recep-
tor antagonist arylazido aminopropionyl ATP (ANAPP3) inhibits the
initial constriction, but has no effect on the secondary sustained con-
traction, indicating the presence of an ATP-mediated component. The
opposite is seen during a-adrenergic receptor blockade with the a1-
-adrenergic receptor antagonist prazosin. The ATP-mediated con-
tractile response is also eliminated by application of tetrodotoxin, a
potent neurotoxin that inhibits voltage-gated sodium channels im-
portant for vesicular exocytosis at nerve terminals, further supporting
release of ATP from sympathetic nerves by vesicular exocytosis.21
Endothelial cells lining the vessel lumen are constantly subjected to
conditions of varying blood flow and shear stress. The release of vaso-
active substances including ATP during conditions of increased shear
stress has been extensively documented.9,16,60 The mechanism re-
sponsible for this event, however, is currently a topic of investigation.
It has been proposed that similar to ATP release from sympathetic
perivascular nerve terminals, endothelial cells may release ATP in a
vesicular manner. Labelling of intracellular ATP with quinacrine, a
quinolone-acridine derivative that has a high binding affinity for
ATP,61,62 in cultured human umbilical vein endothelial cells
(HUVECs) revealed a punctate staining pattern within the cell consist-
ent with intracellular vesicles.63 Moreover, pretreatment of HUVECs
with monensin, an inhibitor of vesicle formation at the Golgi, resulted
in a significant decrease in quinacrine fluorescence when compared
with untreated cells, consistent with localization of ATP to intracellu-
lar vesicles in these cells. Stimulation of quinacrine-labelled endothelial
cells by increasing the shear stress at 10 or 25 dynes/cm2 lead to a
rapid decrease in quinacrine fluorescence and increase in ATP con-
centration in the extracellular media, suggesting release of ATP
stores via an exocytotic mechanism. In contrast, unstimulated cells
showed little detectable ATP in the extracellular medium. Also, mon-
ensin was shown to abolish the release of ATP from cultured
HUVECs exposed to a shear stress of 25 dynes/cm2. These observa-
tions suggest that vesicular exocytosis of ATP from endothelial cells
could occur during changes in vessel blood flow and shear stress.
While evidence has surfaced suggesting the vesicular release of ATP
from different tissues, the question has remained how ATP from the
cytosol is packaged into secretory vesicles. Recently, a vesicular nu-
cleotide transporter, termed VNUT, was identified in a number of se-
cretory cell types.64 This transporter was found to be localized to
intracellular vesicles and was active in pumping ATP into the vesicle
lumen, utilizing a proton gradient established by the vacuolar-ATPase
(v-ATPase). Hydrolysis of ATP by v-ATPase drives the translocation of
protons across the vesicular membrane, concentrating them in the
vesicle lumen.65 Although the establishment of a proton gradient
creates both an electrochemical potential difference as well as pH gra-
dient across the vesicular membrane, the activity of VNUT has been
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shown to be solely dependent on the electrochemical difference.64
While VNUT fulfils the role of a transporter for concentrating ATP
into intracellular vesicles, it remains to be established whether this
transporter is expressed and active in perivascular sympathetic
nerves and endothelial cells.
2.2 ABC transporters
The ABC transporters are a class of integral membrane proteins that
utilize the energy of ATP hydrolysis to facilitate the movement of a
large array molecules across the plasma membrane of cells, including
cholesterol, lipids and many hydrophobic drugs.66 Each member of an
ABC transporter has two conserved intracellular ATP-binding
domains that bind and hydrolyse ATP. Three of these proteins,
the cystic fibrosis transmembrane conductance regulator (CFTR),
the multidrug resistance gene product mdr (also known as P-
glycoprotein), and the sulfonylurea receptor (SUR) have been sug-
gested to not only utilize ATP as an energy source for active trans-
port, but to physically transport the purine nucleotide out of the
cell for autocrine/paracrine purinergic signalling.67– 69 With the
search for a channel or transporter that is responsible for ATP
release in a multitude of cell types, the ABC transporters have
become a potential candidate to fill this role. To date, however,
much work is focused on determining whether these membrane
transporters are capable of transporting ATP out of the cell them-
selves, or whether they regulate the activity of another channel or
transporter responsible for the event.
In 1989, the gene responsible for cystic fibrosis (CF) was identified.
Characterization of its gene product, CFTR, revealed a transmem-
brane transport protein belonging to the ABC transporter family
that is involved in cellular chloride homeostasis.70– 72 CFTR has
been shown to produce a small Cl2 current itself, and it is thought
that activation of CFTR by cAMP-dependent protein kinase A
(PKA) regulates the activity of a large-conductance outwardly rectify-
ing chloride channel (ORCC), whose activity is also absent in CF
patients lacking the functional CFTR gene. Elucidation of the mechan-
ism mediating this event in epithelial cells has revealed that cAMP-
dependent activation of CFTR results in the release of ATP, which
can then bind and activate P2 purinergic receptors in an autocrine/
paracrine signalling mechanism and stimulate Cl2 efflux from the
cell by activation of ORCCs.73 In agreement with these findings,
whole-cell and inside-out patch clamp recordings of cells transfected
with CFTR revealed ATP currents that were dependent on cAMP and
PKA activation, which were absent in cells lacking the ABC transport-
er.68 Related studies show ATP currents in cells expressing the mul-
tiple drug resistance gene product P-glycoprotein, another member
of the ABC transporter family, further supporting a functional role
for this family of proteins in the release of ATP.67 While the major
focus of the ATP release from CFTR has been in epithelial cell physi-
ology, this transporter has been identified in vascular smooth muscle
cells,74 endothelial cells,75 and circulating erythrocytes25 and plate-
lets76 providing a potential conduit for ATP release into from
these cells.
Erythrocytes from CF patients with mutations in CFTR show
marked reductions in ATP release upon membrane deformation, a
stimulus known to induce ATP release from these cells. Also, incuba-
tion of erythrocytes from healthy donors with glibenclamide, a sulfo-
nylurea drug shown to inhibit ABC transporters and the ATP-sensitive
K+ channel (KATP), or niflumic acid, an inhibitor of cyclooxygenase-2
that has been proposed to inhibit CFTR, results in a significant
decrease in deformation-induced ATP release.25 However, it should
be noted that the pharmacology associated with these studies is com-
plicated by non-specific drug interactions with targets other than
CFTR. Nonetheless, the role for CFTR in ATP release from erythro-
cytes is further supported by studies showing that constitutive activa-
tion of PKA, a mechanism known to regulate CFTR activity, by
incubation with the active S-stereoisomer of cAMP causes increased
ATP release, whereas incubation with the inactive R-stereoisomer
does not.77
The SUR, recently identified as a member of the ABC transporter
family, has been shown to form a functional complex with the KATP
channel.78 Buildup of intracellular ATP causes membrane depolariza-
tion by directly inhibiting potassium efflux through the constitutively
active KATP channel. The sulfonylurea drug glibenclamide is known
to inhibit potassium currents from the KATP channel. This event has
been suggested to occur through direct action on SUR to inhibit
ATP efflux from the cell and increase the intracellular concentration
of ATP. Indeed, activation of KATP currents by diazoxide, a sulfony-
lurea known to activate KATP channels in pancreatic beta cells,
79 is de-
pendent on the presence of releasable intracellular ATP.80 In the rat
pulmonary vasculature, flow-induced release of ATP by the endothe-
lium and the resultant vasodilation can be attenuated by luminal per-
fusion with glibenclamide.81 This observation might be explained by
inhibition of ATP release from SUR on endothelial cells, or by inhib-
ition of ATP release from CFTR localized to these cells. Ultimately,
inhibition of ATP release from either of these transporters could
result in decreased autocrine/paracrine signalling through P2Y puri-
nergic receptors on the endothelium which may explain the attenu-
ated vasodilation. The release of ATP through CFTR in the vascular
endothelium has not been directly examined, but the expression
and Cl2 channel activity of CFTR have been observed in these cells.75
While the studies presented above have suggested a role for ABC
transporters in directly releasing ATP from cells, studies have
emerged opposing this idea. Importantly, it has been shown that
CFTR reconstituted in planar lipid bilayers failed to conduct ATP,
and CFTR in stably transfected mammalian cell lines, as well as en-
dogenous CFTR in intact organs and human lung cell lines was not
involved in the release of ATP from these cells.82 These studies had
a large impact in silencing the notion that ABC transporters may be
involved in releasing ATP from cells; however, more recently, a
novel study implicating CFTR in acidosis-induced ATP release from
skeletal muscle cells has re-ignited the potential for ABC transporters
in releasing ATP. In this study, the authors noted a significant decrease
in the amount of ATP release from acidotic skeletal muscle cells upon
blockade of CFTR with the selective CFTR inhibitor CFTRinh172 and
by selective knockdown of CFTR with siRNA.83 These studies suggest
a functional role for CFTR and other ABC transporters as ATP
release channels. Expression of these proteins in the vascular
endothelium as well as in vascular smooth muscle cells74,84 may
provide a potential mechanism for ATP release from these cells,
warranting further investigation into their functional role in the
vascular system.
2.3 Plasma membrane F1F0-ATPase
The process of oxidative phosphorylation in the mitochondria sets up
an electrochemical proton gradient across the inner mitochondrial
membrane that is utilized by the mitochondrial F1/F0-ATP synthase
(referred to as ATP synthase) to drive the synthesis of ATP in the
mitochondrial matrix. This enzyme is composed of the F0 membrane
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bound subunit, which anchors the protein in the inner mitochondrial
membrane and houses the pore where proton transport takes place,
and the catalytic F1 subunit, which extends into the mitochondrial
matrix and catalyses the formation of ATP from ADP and inorganic
phosphate (for review see85). While it was originally thought that
ATP synthase was localized and active only in the mitochondria,
recent evidence has detected the enzyme at the plasma membrane
of a number of cell types, including vascular endothelial cells.86– 89
Angiostatin, a product of plasminogen cleavage in the fibrinolytic
system, exhibits high affinity binding to the alpha and beta subunits
of the F1 subunit of ATP synthase in membrane fractions from
HUVECs and has been identified as a potent inhibitor of angiogenesis
and tumour development.86,90,91 The anti-angiogenic effects of angios-
tatin are thought to be mediated by inhibition of ATP release as extra-
cellular ATP is suggested to be a pro-angiogenic factor for endothelial
cells.92 Binding of angiostatin to the F1 subunit of plasma membrane
ATP synthase in endothelial cells inhibits its activity and the formation
of extracellular ATP.93 In these cells, immunocytochemistry per-
formed under non-permeablizing conditions revealed surface expres-
sion of the F1 subunit further indicating an extracellular localization of
the ATP synthase catalytic head. In the vasculature, endothelial cells
exposed to increases in blood flow and shear stress release ATP
into the lumen to promote vasodilation. Measurement of ATP in
the media from cultured human pulmonary artery endothelial cells
exposed to increased flow conditions revealed a flow-dependent in-
crease in ATP release that could be inhibited by angiostatin as well
as by an antibody directed against the beta subunit of the F1 catalytic
head.18 These observations present a potential mechanism by which
endothelial cells in the blood vessel lumen can release ATP in re-
sponse to haemodynamic forces. As ATP synthase utilizes a proton
motive force for ATP generation, the mechanism of its activation by
increased flow remains to be elucidated. In order to synthesize ATP
at the extracellular surface of the endothelial cell plasma membrane,
a proton gradient must be established across the cell membrane local
to the ATP synthase, which could potentially affect the intracellular
pH and have detrimental effects on the activity of a number of intra-
cellular proteins by acidifying the regions of the cytosol. Importantly,
as this enzyme catalyses the formation of ATP from ADP and inorgan-
ic phosphate, these metabolites must be present in the blood vessel
lumen in concentrations sufficient to promote ATP synthase activity.
The activity of ectonucleotidases and soluble nucleotidases in the
plasma may also potentiate degradation of these precursor molecules.
Nonetheless, the ectopic expression of the ATP synthase at the
plasma membrane of vascular endothelial cells suggests that this
protein may be involved in regulating vascular purinergic signalling
events. Future studies may provide insights into this novel mechanism
of ATP release from cells.
2.4 Connexin hemichannels
Connexins (Cx) are vertebrate gap junction proteins that form hex-
americ oligomers (called connexons) in the endoplasmic reticulum
and Golgi, which are then trafficked to and inserted into the plasma
membrane of cells.94 When a connexon from one cell is in close ap-
position to a connexon expressed on an adjacent cell, the two pro-
teins can form non-covalent linkages between their extracellular
loops, creating an intercellular gap junction channel that connects
the cytosol of the two cells. Gap junctions mediate cell-to-cell com-
munication by the transport of intracellular signalling molecules and
second messengers less than 1 kDa, as well as propagation of
membrane potential currents between joined cells.95– 97 To date,
about 20 mammalian connexin isoforms have be identified, and the
role of these proteins in gap junctional communication has been ex-
tensively characterized. However, there have been reports of
undocked connexons or hemichannels at the surface of a number
of cell types, including astrocytes and glia in the central nervous
system,98– 100 circulating polymorphonuclear granulocytes101 and
monocytes,102 vascular endothelial cells,19,103 –105 and vascular
smooth muscle cells.106 It has been proposed that these hemichannels
may function as conduits for the transport of molecules, including
ATP, between the cytosol of a cell and the extracellular
space.107,108 Under resting physiological conditions, connexin hemi-
channels remain in a closed impermeable state, but it has been sug-
gested that stimuli including decreases in extracellular Ca2+
([Ca2+]e),
109,110 strong membrane depolarizations,111,112 mechanical
stimulation,104,105 and metabolic inhibition113 are capable of opening
these hemichannels. Dye uptake experiments are a commonly used
experimental technique to evaluate the permeability of membrane
channels to dyes of varying molecular weights. Li et al.108 demon-
strated that a decrease in [Ca2+]e resulted in cellular uptake of mul-
tiple low-molecular weight dyes in HeLa cells transfected to
overexpress Cx43 and normal rat kidney cells. Moreover, dye
uptake in a Novakoff hepatoma cell line was markedly reduced
upon expression of an antisense Cx43 vector and significantly
increased upon over expression of the protein, indicating activity of
Cx43 hemichannels in mediating this event. Analysis of the biophysical
properties of hemichannels composed of Cx43 revealed an ionic con-
ductance of 220 pS during electrophysiological patch clamp studies
in HeLa cells overexpressing Cx43. This measured conductance was
approximately twice that observed for gap junctions, indicating that
the measured currents were produced by opening of connexin hemi-
channels and not gap junctions.111 Moreover, ATP liberation by C6
glioma cells overexpressing Cx43 was detected in both whole-cell
and inside-out patch clamp studies coupled to bioluminescence
assays, whereas no detectable ATP release was measured in cells
expressing a truncation mutant or GFP-tagged Cx43. Both of these
modifications have been shown to eliminate channel activity. Also,
ATP release from Cx43 expressing cells was attenuated by the add-
ition of two different non-specific gap junction blockers, gadolinium3+
and carbenoxolone.114 In addition, cultured astrocytes have been
reported to release ATP through connexin hemichannels, inducing
calcium wave propagation.107 Application of the gap junction inhibitor
flufenamic acid attenuated both dye uptake and ATP release from
these cells, suggesting a mechanism involving transport through con-
nexin hemichannels. In a separate study, inflammatory insults such
as tumour necrosis factor-a and interleukin-1b in the central
nervous system induced ATP and glutamate liberation from astrocytes
via Cx43 hemichannels.98 Altogether, these observations provide evi-
dence for a role of connexin hemichannels in mediating ATP release
from a number of different cell types.
To date, four connexin isoforms are abundantly expressed in the
vascular smooth muscle and endothelial cells that comprise the
blood vessel wall: Cx37, Cx40, Cx43, and Cx45.115,116 Gap junctions
formed by these isoforms have been shown to have important roles in
regulating cross talk between adjacent VSMCs and ECs, as well as
between the two cell types at the myoendothelial junction (for
review see 117). In particular, gap junctions comprised of Cx40 in
the vascular endothelium are important for calcium wave propagation
in conducted vasodilation.118 At the level of the myoendothelial
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junction, the point at which endothelial cells and smooth muscle cells
come into contact through the internal elastic lamina, Cx40 and Cx43,
form gap junctions that allow for the transfer of second messengers
and ions between the two cell types to coordinate vasomotor
responses.119 As these vascular cells highly express connexin proteins,
it is possible that there exists a population of undocked connexin
hemichannels that could provide a conduit for ATP release into the
vessel lumen or extracellular milieu surrounding the vascular media.
Several recent studies have examined the potential for endothelial
cells and smooth muscle cells to release ATP from connexin hemi-
channels. It has been shown that propagation of calcium waves in con-
fluent monolayers of bovine corneal endothelial cells occurs in
response to mechanical stimulation in which a glass micropipette is
used to mechanically perturb the plasma membrane of a cell.105 In
these studies, application of the gap junction blocker flufenamic acid
and the connexin mimetic peptide Gap26 significantly reduced
calcium wave propagation. Dye transfer was not affected, indicating
that the release of a paracrine signalling molecule from connexin
hemichannels elicits a calcium response in an adjacent cell and not
direct transfer of calcium from one cell to another in this system.
Further investigation revealed the release of ATP from these cells
upon mechanical stimulation, as well as increased calcium wave propa-
gation in the presence of the CD39 inhibitor ARL67156. The results
of this study suggest a role for a distinct pool of connexin hemichan-
nels at the non-junctional membrane of endothelial cells in the cornea
that are capable of releasing ATP to promote calcium wave propaga-
tion through a paracrine signalling mechanism during mechanical
stress. In the juxtaglomerular vasculature of the renal system, glom-
erular endothelial cells (GENCs) propagate calcium waves to regulate
renal blood flow and the glomerular filtration rate through the release
of ATP and purinergic signalling mechanisms.120 Mechanical stimula-
tion of cultured GENC resulted in the formation of calcium waves
that were inhibited by the gap junction uncoupler 18a-glycyrrhetinic
acid (18a-GA) and by siRNA knockdown of Cx40 in these cells. As
Cx40 is highly expressed and is capable of coupling GENCs through
gap junctions, the contributions of ATP release and purinergic signal-
ling mechanisms to the observed calcium wave were evaluated by ap-
plication of an ATP scavenging cocktail consisting of hexokinase, a
glycolytic enzyme that utilizes high amounts of ATP, and apyrase to
degrade extracellular ATP. During mechanical stimulation in the pres-
ence of the cocktail, calcium wave propagation between adjacent
GENCs was greatly attenuated with no significant effect on dye trans-
fer between cells, indicating a role for extracellular ATP in mediating
calcium wave propagation. The authors utilized an ATP biosensor
assay to measure ATP release from cultured GENCs. The biosensor
system consisted of loading PC12 cells, which express a variety of pur-
inergic receptors, with the calcium indicator dye Fluo-4 and applying
them to a confluent monolayer of GENCs. In response to the mech-
anical stimuli, GENCs released ATP, which bound to purinergic recep-
tors on the PC12 cells, thereby eliciting an increase in intracellular
calcium as detected by Fluo-4 fluorescence, which enabled direct
quantification of ATP release from the endothelial cells. This response
was attenuated by inhibiting the purinergic receptors on PC12 cells
with the non-selective P2 purinergic receptor antagonist suramin,
which validated the specificity of their biosensor system to extracel-
lular ATP. The mechanically induced release of ATP from GENCs
was abolished by siRNA knockdown of Cx40 and could be restored
by addition of exogenous ATP to the system.104 Altogether, these dif-
ferent studies suggest that these endothelial cells express undocked
connexin hemichannels at the plasma membrane, which are capable
of releasing ATP in response to mechanical stimulation.
While hypoxia has been suggested to increase flow-induced ATP
release from endothelial cells,9 it has also been suggested that
hypoxia inhibits ATP liberation by Cx43 hemichannels in the endothe-
lium.19 The authors of the latter study concluded that hypoxia
decreased ATP release from cultured endothelial cells by down regu-
lation of Cx43 mRNA and hemichannel expression at the plasma
membrane, as well as an upregulation of Cx43 phosphorylation at
Ser368,121 which has been shown to inhibit channel activity. This ob-
servation suggests that connexin hemichannels may be implicated in
ATP release under certain conditions; however, they do not play a
role in hypoxia-induced ATP release from endothelial cells.
Connexin hemichannels may play an important role in the liber-
ation of ATP during pathologies, such as acute infection, inflammation,
and atherosclerosis. Endothelial cells exposed to the gram-positive
bacterial wall component peptidoglycan (PDG) derived from Staphylo-
coccus epidermidis have been shown to release ATP through Cx43
hemichannels.103 This study revealed an increase in Cx43 mRNA as
well as induction of the pro-inflammatory cytokine interleukin-6 and
Toll like receptor 2 in endothelial cells in response to PDG. The in-
duction of this inflammatory cascade was coupled to increased
Cx43 hemichannel activity at the plasma membrane of these cells
and release of ATP into the media.
During atherosclerosis, circulating monocytes adhere to and
migrate across the vascular endothelium where they differentiate
into macrophages and foam cells in the subintimal space, eventually
leading to atherosclerotic plaque formation and narrowing of the
vessel lumen (for review see 122). A novel study by Wong et al.102
indicated a protective role for ATP released from circulating mono-
cytes via Cx37 hemichannels during atherosclerosis. Complete
genetic knockout of Cx37 in the proatherogenic ApoE2/2 mouse
line resulted in a marked increase in atherosclerotic lesion formation
and area. Further investigation revealed that monocytes from the
Cx372/2/ApoE2/2 mice had a significant decrease in basal ATP
release when compared with those from mice expressing functional
Cx37. This reduction in ATP liberation from monocytes lacking
Cx37 resulted in a significant increase in monocyte adhesion to cul-
tured endothelial cells, supporting their in vivo evidence for increased
plaque formation and size. Monocyte adhesion was also increased in
response to connexin hemichannel blockade by 18a-GA, and the
connexin mimetic peptides Gap26 and Gap27. In a separate study, ac-
tivation of neutrophils with fMLP (N-formyl Met-Leu-Pro) induced
ATP release that resulted in decreased endothelial cell permeabil-
ity.101 Release of ATP from these cells was significantly reduced
upon addition of the Cx43-specific mimetic peptide 43Gap26 as
well as from Cx432/2 neutrophils, indicating a release mechanism in-
volving Cx43 hemichannels. The released ATP was actively degraded
to adenosine by the activity of CD39 expressed on the neutrophils
themselves and CD73 expressed on endothelial cells. Binding of ad-
enosine to A2a adenosine receptors on the endothelial cells resulted
in decreased paracellular permeability. The mechanisms surrounding
A2a adenosine receptor-mediated changes in endothelial cell perme-
ability have also been investigated.123 While the data presented above
suggest a role for ATP release from Cx hemichannels in circulating in-
flammatory cells as a protective mechanism against infiltration into the
vascular wall, a host of literature suggests that ATP promotes vascular
smooth muscle cell migration and proliferation through purinergic sig-
nalling mechanisms.13,14,124 It has also recently been shown that
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fibroblasts release ATP from connexin hemichannels promoting pro-
fibrotic responses in the heart125 and these observations may suggest
a role for resident vascular fibroblasts to release ATP via this mech-
anism to promote purinergic signalling in the blood vessel wall.
Taken together, connexin hemichannels may be important for regulat-
ing ATP release in the blood vessel lumen to modulate endothelial cell
permeability, while differential ATP release mechanisms in the vascu-
lar media may be involved in modulating vascular smooth muscle cell
phenotype, such as ATP released from parasympathetic nerves.126
Altogether, the data presented above support a potential role for
connexin hemichannels in ATP release under pathological (e.g. inflam-
matory insults, atherosclerosis, decreased [Ca2+]e) and possibly
physiological conditions; however, it remains to be elucidated as to
whether connexin hemichannels play a role in ATP release from vas-
cular cells for the regulation of vascular tone and blood pressure.
2.5 Pannexin channels
In 2000, a novel protein family was identified termed pannexins (Panx)
that are orthologs of the invertebrate gap junction proteins, the
innexins, and share a similar membrane topology to mammalian gap
junction proteins, connexins.127 To date, three pannexin isoforms
have been identified (Panx1, Panx2, and Panx3), and the distribution
of each across different tissues and cell types is a current topic of in-
vestigation. Panx1 and Panx3 are believed to assemble into hexamers,
while Panx2 may form heptamers or octamers.128,129 The pannexins
are assembled in the ER and Golgi and are transported to the
plasma membrane in a fashion similar to the connexins; however,
the pannexins do not form gap junctions and therefore their nomen-
clature is designated as pannexin channels and not hemichannels.130
This key difference is likely due to the fact that the pannexins are
highly glycosylated on their extracellular loops, which may impede
docking with pannexin channels on neighbouring cells.131,132 There-
fore, it has been suggested that pannexins form membrane channels
that allow transport of molecules between the intra- and extracellular
space. Upon characterization of the properties of the channels
formed by pannexins in a heterologous expression system, it was
observed that unlike connexin hemichannels, pannexin channels are
not regulated by [Ca2+]e, allowing these channels to open under
physiological [Ca2+]e.
133 Expression of Panx1 in xenopus oocytes
revealed maxi anion currents upon membrane depolarization with
KCl, and patch clamp studies demonstrated the permeability of
these channels to ATP.134 This observation has since prompted mul-
tiple studies investigating the role of Panx1 channels in ATP release
from a number of cell types, including: astrocytes, glial cells and
neurons in the central nervous system,135– 140 T-cells,141 – 143 airway
epithelia,144,145 taste cells,146 keratinocytes,147 circulating erythro-
cytes,27,50 and vascular smooth muscle cells and endothelial
cells.11,148 While Panx1 channels constitute ATP release channels
that function under physiological conditions, there have also been
reports implicating these proteins in apoptosis and cell death,149 as
well as in activation of T-cells during inflammation.141 – 143 Therefore,
much effort is currently devoted to identifying the mechanisms that
regulate pannexin channel permeability to purines and other intracel-
lular molecules, as well as potential binding partners that may regulate
the release of ATP through these channels.
During cellular apoptosis, dying cells release nucleotides into the
extracellular space to promote phagocyte chemotaxis, engulfment,
and clearance. Recent evidence has implicated Panx1 channels in
mediating ATP release during this process. Chekeni and co-authors
observed activation of Panx1 channels in apoptotic cells induced by
caspase cleavage of the intracellular carboxy-tail of Panx1. More
recent evidence has characterized the importance of the Panx1
C-tail in the regulation of channel permeability.150 This event resulted
in ATP release into the extracellular milieu and recruitment of phago-
cytes. The release of ATP as well as monocyte and leucocyte recruit-
ment to cells stimulated with anti-Fas or UV light, both of which are
known pro-apoptotic stimuli, were significantly attenuated upon
knockdown of Panx1 with Panx1 siRNA, indicating that these channels
are the conduit for ATP release and promotion of apoptotic cell
clearance.149 While this study indicates a role for ATP release from
Panx1 in cell death, ATP release from Panx1 has been shown to be
protective during pathological insults such as ischaemia. In astrocytes,
ischaemic stress has been shown to suppress the release of ATP to
protect against cellular death and promote survival. This protection
from ischaemic insult was suggested to occur through inhibition of
ATP release from Panx1 channels, by a negative feedback mechanism
involving the P2X7 purinergic receptor.
136 Prolonged activation of P2X7
receptors results in the opening of a large pore permeable to divalent
cations such as Ca2+ that eventually leads to cell death.151– 153 This
study revealed that ischaemic insult to cultured cortical astrocytes
resulted in initial ATP release from Panx1 channels that in turn acti-
vated P2X7 receptors, inducing closure of Panx1 channels, which pre-
vented the loss of integral intracellular constituents and averted cell
death. Together, these studies identify differential roles for Panx1 in
pathological states.
While evidence is accumulating that supports pannexins as ATP
release channels across cell types, their expression and activity in
the vasculature are a current topic of investigation. Initial studies
have identified key roles for Panx1 channels in regulating ATP
release from circulating erythrocytes during hypoxia and during mem-
brane deformation,27,50 from vascular smooth muscle cells upon a1D-
adrenergic receptor activation,11 and from endothelial cells in re-
sponse to thrombin stimulation.148 Liberation of ATP from these
cells occurs under physiological calcium concentrations and may
play pivotal roles in regulating vessel tone and peripheral resistance.
Initial evidence has suggested that ATP release from circulating ery-
throcytes in response to low oxygen tension occurs through the
ABC-transporter CFTR25 (see ATP binding cassette transporters
section); however, recent studies have presented conflicting evidence
for the ability of ABC transporters to release ATP.154,155 A recent
study by Locovei et al. demonstrated that ATP release during depolar-
ization of erythrocytes by high extracellular K+, as well as decreased
oxygen tension, was inhibited by the gap junction blocker carbenox-
olone. The authors noted that the erythrocytes in this study had no
detectable Cx43 expression, further suggesting that carbenoxolone
inhibited Panx1 channels and not Cx hemichannels. While carbenox-
olone has been shown to inhibit connexins as well as pannexins, the
EC50 for pannexin inhibition is 5 mM, whereas incubation of
xenopus oocytes expressing Cx46 (the model connexin isoform for
examining properties of connexin hemichannels) with .10 mM car-
benoxolone had no effect on hemichannel current.133 In a separate
study, inhibition of ATP release from erythrocytes exposed to low
oxygen tension was evaluated in the presence of three separate inhi-
bitors of pannexin channels, carbenoxolone, probenecid, and the
blocking peptide 10Panx1.27 This study revealed that the treatment
of human erythrocytes with any of these three inhibitors significantly
attenuated low oxygen tension-induced ATP release, further
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Figure 1 Mechanisms of ATP release from cells of the blood vessel wall. Representative illustration of the currently proposed mechanisms of ATP
release from endothelial cells, vascular smooth muscle cells, perivascular sympathetic nerves, and circulating erythrocytes in the vascular system. Cyto-
solic ATP available for release from these cells is generated by glycolysis in the cytosol and oxidative phospohorylation in the mitochondria. In sym-
pathetic nerves, ATP release has been shown to occur via vesicular exocytosis. Vascular smooth muscle cells have been suggested to release ATP
through membrane transporters and channels, including connexin hemichannels and pannexin channels, as well as potentially by ABC transporters.
Vascular endothelial cells have been proposed to release ATP via vesicular exocytosis, ABC-transporters, connexin hemichannels, pannexin channels,
and by direct synthesis at the extracellular plasma membrane by a cell surface F1/F0-ATP synthase. Circulating erythrocytes have been suggested to
release ATP through ABC transporters and via pannexin channels.
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supporting a functional role for Panx1 channels in ATP release from
circulating erythrocytes under these conditions.
Vascular smooth muscle cells in small arteries that are involved in
regulation of blood flow and blood pressure have been shown to con-
tract in response to a-adrenergic receptor stimulation. Sympathetic
nervous impulses elicit release of the catecholamine norepinephrine
from nerve terminals innervating vascular beds resulting in activation
of the a1D-adrenergic receptor, an increase in smooth muscle cell
[Ca2+]i and vasoconstriction, ultimately producing an increase in per-
ipheral resistance and blood pressure.156 The Isakson laboratory re-
cently identified a novel role for Panx1 channels in regulating the
a1-adrenergic receptor mediated response.
11 In this study, stimulation
of isolated pressurized thoracodorsal arteries with the a1-adrenergic
receptor agonist phenylephrine (PE) resulted in strong vasoconstric-
tion, consistent with previous observations. Recent characterization
of the thoracodorsal artery has shown that it is highly innervated by
adrenergic nerves, develops spontaneous tone, and responds to
various vasoactive agents similar to other small resistance artery
models.157 In the presence of three different pannexin inhibitors pro-
benecid, mefloquine, and 10Panx1 blocking peptide, the constriction
to PE was significantly reduced. Also, application of apyrase to the
superfusion bath surrounding the blood vessel resulted in a similar in-
hibition of contraction. Finally, stimulation of cultured human coron-
ary arterial vascular smooth muscle cells with PE induced ATP
release from these cells that were significantly attenuated by pretreat-
ment of the cells with the 10Panx1 blocking peptide. Together, these
results identify a novel role for vascular smooth muscle cell Panx1
channels in releasing ATP during a1-adrenergic receptor activation,
a process that is essential for the regulation of vascular tone and
blood pressure. These results indicate a potential therapeutic ap-
proach for blood pressure regulation. It was also observed that ex-
pression of Panx1 in endothelial cells of the blood vessel wall was
significantly enhanced. In addition, Godecke et al.148 recently demon-
strated that HUVECs release ATP in response to thrombin, which was
sensitive to carbenoxolone and knockdown of endogenous Panx1.
Furthermore, analysis of the expression patterns for the different pan-
nexin isoforms in the smooth muscle and endothelial cells across the
arterial tree suggests increased expression in smooth muscle cells as
vessel diameter decreases, supporting the idea that ATP release from
Panx1 channels in vascular smooth muscle cells of small arteries and
arterioles may play an important role in regulating blood flow.158
To date, little is known about the role of Panx channels in the regu-
lation of physiological processes, in particular those involving the vas-
culature and blood flow dynamics. However, characterization of the
pharmacological properties of a number of gap junction inhibitors
has suggested that some of the previous studies identifying connexin
hemichannels as the cellular pathway for ATP release may potentially
be due to activity of Panx channels.159 Further investigation into the
expression patterns and regulatory mechanisms governing Panx
channel activity in vascular endothelial and smooth muscle cells will
help reveal novel signalling pathways that may participate in the regu-
lation of vascular tone, peripheral resistance, and blood pressure,
which could provide new targets for therapeutic intervention for
the treatment of hyper/hypotension.
3. Conclusion
The release of intracellular ATP into the extracellular space promotes
signalling through purinergic receptors that have been extensively
characterized in multiple cell types and experimental systems. Import-
antly, evidence for purinergic signalling in the regulation of vascular
tone at both vascular smooth muscle and endothelial cells warrants
investigation into how this purine nucleotide is released from the
cells. Current studies have proposed mechanisms of ATP release by
vesicular exocytosis, transport through ABC transporters, a plasma
membrane F1/F0-ATP synthase, and liberation via connexin hemichan-
nels or pannexin channels (Figure 1). The stimuli used to evoke ATP
release from vascular cells in these studies have varied and important-
ly it must be noted that quantification of ATP in cell supernatants can
easily be confounded by stimuli that induce cell lysis. Because cells
contain millimolar amounts of cytosolic ATP, rupture of even a
single cell in a given preparation can release a sufficient amount of
ATP to elicit physiological effects (i.e. Ca2+ wave propagation160)
and may dramatically skew the quantification and interpretation of
ATP released from cells. In particular, it has recently been noted
that increases in shear stress on endothelial cells can induce cell
lysis, which may be the rational for the noted increase in extracellular
ATP.161 It is also not known whether the different pharmacological
agents employed to evaluate the mechanisms of ATP release have
effects on lytic-ATP release. It is therefore essential that experiments
evaluating ATP release by quantification in cell supernatants be con-
trolled for lytic-ATP release. Nonetheless, the studies reviewed
above have examined ATP release from cells in the vasculature by
multiple mechanisms and promote the idea that differential release
mechanisms may be employed during specific physiological and patho-
logical situations. However, the recently identified Panx1 channels
have been shown to be closed at resting membrane potentials and
are capable of opening in the presence of physiological extracellular
calcium, in response to a1-adrenergic receptor activation and
hypoxia and are ubiquitously expressed throughout the vasculature.
These results support the notion that Panx channels may be the
physiologic ATP release channels in the vascular system. The identifi-
cation of Panx1 in the vascular endothelium raises the possibility that
ATP released from these cells during periods of increased shear stress
and hypoxia, or in response to other signalling mechanisms such as
thrombin-induced ATP release, may occur by activation of these chan-
nels. Further investigation into the regulatory mechanisms of Panx
channels in the vascular endothelium and smooth muscle cells, as
well as circulating erythrocytes, may reveal new insight on the
control of peripheral vascular resistance and blood pressure and
introduce new drug targets for the treatment of vascular disease.
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